These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 18159152)
1. [Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis]. Park JI; Choi KM; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Chung YH; Lee YS; Suh DJ Korean J Hepatol; 2007 Dec; 13(4):543-55. PubMed ID: 18159152 [TBL] [Abstract][Full Text] [Related]
2. Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience. Abdel-Wahab M; Abdel-Khalek EE; El-Gilany AH; Yassen AM; Al-Shobari M; Shiha U; Ali M; Sadani M; Salah T; Sultan AM; Elghawalby AN; Elmorshedi M; Al-Refaey AK; Abdalla U Arab J Gastroenterol; 2017 Sep; 18(3):151-155. PubMed ID: 28958486 [TBL] [Abstract][Full Text] [Related]
3. Sustained virological response: a milestone in the treatment of chronic hepatitis C. Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416 [TBL] [Abstract][Full Text] [Related]
4. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation. Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382 [TBL] [Abstract][Full Text] [Related]
5. Recurrent hepatitis C virus infection and outcome after living-donor liver transplant. Satapathy SK; Fiel MI; Vanatta JM; Del Rio Martin J; Schiano TD Exp Clin Transplant; 2013 Dec; 11(6):522-9. PubMed ID: 23901801 [TBL] [Abstract][Full Text] [Related]
6. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study. Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination. Ohara T; Oteki T; Suzuki T; Suzuki M; Matsuzaki Y Hepatogastroenterology; 2011; 58(105):133-6. PubMed ID: 21510300 [TBL] [Abstract][Full Text] [Related]
8. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Ueda Y; Takada Y; Marusawa H; Egawa H; Uemoto S; Chiba T Transplantation; 2010 Sep; 90(6):661-5. PubMed ID: 20110853 [TBL] [Abstract][Full Text] [Related]
9. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854 [TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases. Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Yedibela S; Schuppan D; Müller V; Schellerer V; Tannapfel A; Hohenberger W; Meyer T Liver Int; 2005 Aug; 25(4):717-22. PubMed ID: 15998420 [TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839 [TBL] [Abstract][Full Text] [Related]
13. [Review: clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis]. Kim HJ Korean J Hepatol; 2007 Dec; 13(4):489-94. PubMed ID: 18159146 [No Abstract] [Full Text] [Related]
14. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570 [TBL] [Abstract][Full Text] [Related]